MARKET PULSE-Enzymotec, Rubicon Project, Summer Infant, Gramercy Property

Wed May 14, 2014 12:58pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(For more market insights, including options activity, click on ; for the Day Ahead newsletter; for the Morning News Call newsletter, U.S. stocks edged lower on Wednesday, with the Dow and S&P 500 both coming off their record closing highs, though losses were concentrated in small-cap names. The Dow Jones industrial average was down 0.36 percent at 16,656.07, and the S&P 500 was down 0.19 percent at 1,893.84.

** SEARS HOLDINGS CORP, $42.61, -1.43 pct

The department store operator said it was considering the sale of its 51 percent stake in Sears Canada Inc, a move that could mean all of the Canadian department store operator goes up for sale.


The pharmaceutical company said it would acquire the U.S. marketing rights to GlaxoSmithKline's migraine drug Treximet for an upfront payment of $250 million.

Acquiring the rights to the drug, which had annual sales of $78.7 million in 2013, will nearly double Pernix's revenue, the company said.

** SUMMER INFANT INC, $2.45, +47.59 pct   Continued...